Mitapivat

Major

Mitapivat Flibanserin Addyi Reduced CYP3A substrate exposure Details Mitapivat Fluconazole Diflucan Increased mitapivat exposure Details Mitapivat Fluticasone Aller-Flo Reduced CYP3A substrate exposure Details Mitapivat Fosamprenavir Lexiva Increased mitapivat exposure Details Mitapivat Fosaprepitant Emend Injection Reduced CYP3A substrate exposure Details Mitapivat Fosnetupitant Increased mitapivat exposure Details Mitapivat Fosphenytoin Cerebyx Reduced phenytoin or fosphenytoin (prodrug of phenytoin) exposure, reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Ganaxolone Ztalmy Reduced ganaxolone exposure and reduced efficacy of ganaxolone Details Mitapivat Gepirone Exxua Reduced CYP3A substrate exposure Details Mitapivat Gepotidacin Blujepa Reduced gepotidacin exposure Details Mitapivat Gestodene Reduced hormonal contraceptive exposure Details Mitapivat Idelalisib Zydelig Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details Mitapivat Imatinib Gleevec Increased mitapivat exposure Details Mitapivat Indinavir Increased mitapivat exposure, an increased risk of mitapivat-related adverse reactions and reduced CYP3A substrate exposure Details Mitapivat Isavuconazole Increased mitapivat exposure and reduced CYP3A4 substrate exposure Details Mitapivat Isavuconazonium Cresemba Increased mitapivat exposure and reduced CYP3A4 substrate exposure Details Mitapivat Itraconazole Sporanox Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details Mitapivat Ivacaftor Kalydeco Reduced CYP3A substrate exposure Details Mitapivat Ivosidenib Tibsovo Reduced ivosidenib exposure, reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Ketoconazole Extina Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details Mitapivat Lazertinib Lazcluze Reduced lazertinib exposure and reduced efficacy of lazertinib Details Mitapivat Lemborexant Dayvigo Reduced lemborexant exposure and reduced efficacy of lemborexant Details Mitapivat Lenacapavir Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir, incr... Details Mitapivat Lercanidipine Reduced CYP3A substrate exposure Details Mitapivat Lesinurad Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Letermovir Prevymis Increased mitapivat exposure Details Mitapivat Levomethadyl Reduced CYP3A substrate exposure Details Mitapivat Lomitapide Reduced CYP3A substrate exposure Details Mitapivat Lonafarnib Zokinvy Increased mitapivat exposure, an increased risk of mitapivat-related adverse reactions and reduced CYP3A substrate exposure Details Mitapivat Lopinavir Reduced lopinavir exposure, reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Lorlatinib Lorbrena Reduced lorlatinib exposure, reduced efficacy of lorlatinib, reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Lumacaftor Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Meperidine Demerol Reduced CYP3A substrate exposure Details Mitapivat Mestranol Reduced hormonal contraceptive exposure Details Mitapivat Midazolam Reduced CYP3A substrate exposure Details Mitapivat Mifepristone Korlym Increased CYP3A4 substrates exposure, reduced miFEPRIStone exposure and reduced efficacy of miFEPRIStone Details Mitapivat Mitotane Lysodren Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Mobocertinib Exkivity Reduced CYP3A substrate exposure Details Mitapivat Modafinil Provigil Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Nafcillin Reduced mitapivat exposure and reduced efficacy of mitapivat Details